PDPK2P and hepatocellular carcinoma: lncRNA-PDPK2P can promote the progression of HCC, suggesting that lncrNA-PDPK2P may be a biomarker of clinical value as a molecular target for diagnosis, prognosis and treatment of hepatocellular carcinoma17.